FDA to ‘rapidly work’ towards emergency use authorization for Pfizer-BioNTech vaccine

The Foodstuff and Drug Administration claimed right now that subsequent yesterday’s beneficial advisory committee conference consequence relating to the Pfizer-BioNTech COVID-19 vaccine, it would speedily function toward finalization and issuance of an emergency use authorization for the COVID-19 vaccine. 

The Fda gave no particular timeline.

The agency has also notified the U.S. Facilities for Sickness Manage and Avoidance and Procedure Warp Velocity, so they can execute their strategies for well timed vaccine distribution.

Approval signifies vaccine distribution would be on Procedure Warp Speed’s plan for distribution to entrance-line health care employees and susceptible populations in extended-expression care services by mid-thirty day period.

The Fda advisory committee has scheduled yet another conference to review the Moderna vaccine on Thursday, December seventeen.

See our continuing vaccine protection here:

Pfizer-BioNTech vaccine will get Fda advisory committee acceptance

CMS presents guidance in billing Medicare for COVID-19 antibody therapy

Hundreds in the United Kingdom are the 1st to get Pfizer COVID-19 vaccine

Eli Lilly and UnitedHealth Group spouse on COVID-19 antibody therapy for higher-danger folks

Procedure Warp Velocity is wanting to begin distributing COVID-19 vaccine by mid-thirty day period

Moderna seeks regulatory authorization for its COVID-19 vaccine

HHS will begin allocating Regeneron’s COVID-19 therapeutic this week

HHS associates with chain and impartial pharmacies to enhance obtain to potential COVID-19 vaccines

COVID-19 vaccine distribution will begin within 24 hours of an emergency use authorization

Moderna vaccine candidate exhibits ninety four.5{79e59ee6e2f5cf570628ed7ac4055bef3419265de010b59461d891d43fac5627} efficacy in opposition to COVID-19

Pfizer touts new COVID-19 vaccine, calling it ’90{79e59ee6e2f5cf570628ed7ac4055bef3419265de010b59461d891d43fac5627} effective’

Medicare beneficiaries can get monoclonal antibody COVID-19 treatment plans at no expense

Fda grants emergency use authorization for Eli Lilly antibody therapy for COVID-19

Twitter: @SusanJMorse
E-mail the author: [email protected]